Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a new treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac. Monopar builds its drug development pipeline through in-house efforts and licensing of late preclinical and clinical-stage therapeutics, leveraging its scientific and clinical expertise to reduce risk and accelerate development. Monopar's team is located in Chicago, IL.

Monopar Therapeutics was incorporated in Delaware on December 16, 2015. It became a public reporting company on January 8, 2018, and began trading on Nasdaq on December 19, 2019. The company is headquartered at 1000 Skokie Blvd. Suite 350 Wilmette, IL 60091.

• 2026.09.01

  Reported2026.08.19

  Monopar Therapeutics appoints Jeffrey D. Kent as Executive Vice President, Head of Medical Affairs[4]Monopar Therapeutics 任命 Jeffrey D. Kent 为执行副总裁兼医疗事务负责人finanznachrichten.de

  Monopar Therapeutics announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. Kent will lead the company's medical affairs organization as Monopar prepares for potential FDA approval of the New Drug Application for ALXN1840 for Wilson disease.

Read more

1. 1Monopar Therapeutics Inc. (MNPR)monopartx.com
2. 2Profile :: Monopar Therapeutics Inc. (MNPR)ir.monopartx.com
3. 3FAQ :: Monopar Therapeutics Inc. (MNPR)ir.monopartx.com
4. 4Monopar Therapeutics 任命 Jeffrey D. Kent 为执行副总裁兼医疗事务负责人finanznachrichten.de